Restricted accessResearch articleFirst published online 2013-12
The efficacy of Botulinum Toxin A for spasticity and pain in adults: a systematic review and meta-analysis using the Grades of Recommendation,Assessment,Development and Evaluation approach
A systematic review and meta-analysis using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach to evaluate Botulinum Toxin Type A efficacy on spasticity and pain in the upper/lower limb in adults.
Data Sources:
Pubmed, Cinahl, Amed, Embase and Cochrane Databases. English language. 1989 to April 2013.
Review methods:
All randomized controlled trials on adults with spasticity of any origin in the upper or lower limb, treated with a single dose of Botulinum Toxin A, with outcome measures for pain or spasticity. Quality was assessed by GRADE, which uses a transparent, structured process for developing and presenting summaries of evidence, including its quality, for systematic reviews.
Results:
A total of 37 studies were reviewed. A meta-analysis was carried out on 10 for pain and 21 for spasticity. Evidence quality was low/very low for pain. No significant effect was found in the upper limb (standardised mean difference (SMD) = 0.44, confidence interval (CI) –0.02 to 0.90, Z = 1.88, P=0.06), and no effect was found in the lower limb (risk ratio (RR) = 1.01 CI 0.19 to 5.36, Z = 0.02, P=0.99).
Evidence quality for spasticity was moderate. Significant effects were found for Botulinum Toxin in the upper limb (weighted mean difference (WMD) = 0.88, CI 0.63 to 1.14, Z = 6.86, P<0.00001), and the lower limb (RR=2.42, CI 1.60 to 3.65, Z=4.18, P<0.0001).
Conclusion:
The use of Botulinum Toxin A is supported for upper and lower limb spasticity. Further evidence is needed for spasticity-related pain. Evidence quality is reduced by inadequate study design.
BhaktaBBCozensJAChamberlainMA. Impact of botulinum toxin Type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry2000; 69: 217–221.
TurkelCBowenBLiuJ. Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil2006; 87: 786–792.
7.
BakheitAMO. Optimising the methods of evaluation of the effectiveness of botulinum toxin treatment of post stroke muscle spasticity. J Neurol Neurosurg Psychiatry2004; 75: 665–666.
8.
Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology. Spasticity in adults: Management using botulinum toxin. National guidelines. London: RCP, 2009.
9.
RawickiBSheeanGFungVSCGoldsmithSMorganCNovakI. Botulinum toxin assessment, intervention and aftercare for paediatric and adult niche indications including pain: international consensus statement. Eur J Neurol2010; 17(S2): 122–134.
10.
GRADE working group. Grading quality of evidence and strength of recommendations. BMJ2004; 328: 1490–1497.
11.
HarbourRMillerJ. A new system for grading recommendations in evidence based guidelines. BMJ200; 323: 334–336.
12.
GuyattGHOxmanADKunzR. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol201; 64: 395–400.
13.
GuyattGHOxmanADAklEA. GRADE guidelines:1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol2011; 64: 383–394.
14.
GuyattGHOxmanADVistGE. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008; 336: 924–926.
15.
CardosoERodriguesBLucenaR. Botulinum toxin type A for the treatment of the upper limb spasticity after stroke—a meta analysis. Arq Neuropsiquiatr2005; 63(1): 30–33.
16.
RosalesRLChua-YapAS. Evidence based systematic review on the efficacy and safety of botulinum toxin A therapy in post stroke spasticity. J Neural Transm2008; 115: 617–623.
17.
Van KuijkAAGeurtsACHBevaartBJWvan LimbeekJ. Treatment of upper extremity spasticity in stroke patients by focal neuronal or neuromuscular blockade: a systematic review of the literature. J Rehabil Med2002; 34: 51–61.
18.
SimpsonDMGraciesJ-MGrahamHK. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence based review): Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology2008; 70: 1691–1698.
19.
GarcesKMcCormickAMcGahanLSkidmoreB. Botulinum toxin A upper and lower limb spasticity: a systematic review [Technology report no 51]. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2005.
20.
OlverJEsquenaziAFungVSCSingerBJWardAB. Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: international consensus statement. Eur J Neurol2010; 17(S2): 57–73.
21.
SinghJAFitzgeraldPM. Botulinum toxin for shoulder pain (review). The Cochrane Collaboration. 2011: Issue 1: 1–51.
22.
LanceJ.W. Symposium synopsis. In: FeldmanRYoungRKoellaW (eds) Spasticity disordered motor control. Year Book, 1980, pp.485–494.
23.
BalshemHHelfandMSchunemannHJ. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol2011; 64: 401–406.
24.
GuyattGHOxmanADVistG. GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol2011; 64: 407–415.
25.
GuyattGHOxmanADMontoriV. GRADE guidelines: 5. Rating the quality of evidence-publication bias. J Clin Epidemiol2011; 64: 1277–1282.
26.
GuyattGHOxmanADKunzR. GRADE guidelines: 6. Rating the quality of evidence- imprecision. J Clin Epidemiol2011; 64: 1283–1293.
27.
GuyattGHOxmanADKunzR. GRADE guideline: 7. Rating the quality of evidence-inconsistency. J Clin Epidemiol2011; 64: 1294–1302.
28.
GuyattGHOxmanADKunzR. GRADE guidelines: 8. Rating the quality of evidence-indirectness. J Clin Epidemiol2011; 64: 1303–1310.
29.
GuyattGHOxmanADSultanS. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol2011; 64: 1311–1316.
HiggensJPTGreenS (editors). Cochrane Handbook for systematic reviews of Interventions Version 5.1.0 (updated March2011). The Cochrane Collaboration, 2011.
32.
De BoerKSArwertHJDe GrootJH. Shoulder pain and external rotation in spastic hemiplegia do not improve by injection of botulinum toxin A into the subscapular muscle. J Neurol Neurosurg Psychiatry2008; 79: 581–583.
33.
KongK-HNeoJ-JChuaSG. A randomized controlled study of botulinum toxin A in the treatment of hemiplegic shoulder pain associated with spasticity. Clin Rehabil2007; 21: 28–35.
34.
RodgersHShawLPriceC. BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Health Technol Assess2010; 14(26): 1–141.
35.
SuputtitadaASuwanwelaNC. The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil2005; 27(4): 176–184.
36.
McCroryPTurner-StokesLBaguleyIJ. Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi centre randomised placebo controlled study of the effects on quality of life and other person-centred outcomes. J Rehabil Med2009; 41: 536–544.
37.
BakheitAMOThilmanAFWardAB. A randomised, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin Type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke2000; 31: 2402–2406.
38.
BakheitAMOPittockSMooreAP. A randomized, double blind, placebo controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. J Neurol2001; 8: 559–565.
39.
ChildersMKBrashearAJozefczykP. Dose-dependent response to intramuscular botulinum toxin type A for upper limb spasticity in patients after stroke. Arch Phys Med Rehabil2004; 85: 1063–1069.
40.
SimpsonDMAlexanderDNO’BrienCF. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomised, double blind, placebo controlled trial. Neurology1996; 46: 1306–1310.
41.
YelnikAPColleFMBonanIVVicoutE. Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: a randomised, double blind, placebo controlled study of botulinum toxin A. J Neurol Neurosurg Psychiatry2007; 78: 845–848.
42.
MarcoEDuarteEVilaJ. Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double blind randomized clinical trial. J Rehabil Med2007; 39: 440–447.
43.
HesseSReiterFKonradMJahnkeMT. Botulinum toxin type A and short term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomised, double blind, placebo controlled trial. Clin Rehabil1998; 12: 381–388.
44.
MarciniakCMHarveyRL. Does Botulinum Toxin type A decrease pain and lessen disability in hemiplegic survivors of stroke with shoulder pain and spasticity. Am J Phys Med Rehabil2012; 91(12): 1007–1019.
45.
RosalesRLKongKHGohKJ. Botulinum Toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: A randomised controlled trial. Neurorehabil Neural Repair2012; 26(7): 812–821.
46.
LamKLauKKSoKK. Can Botulinum Toxin decrease carer burden in long tern care residents with upper limb spasticity? A randomised controlled study. J Am Med Dir Assoc2012; 13: 477–484.
47.
HymanNBarnesMBhaktaB. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomized, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry2000; 68: 707–712.
48.
PittockSJMooreAPHardimanO. A double blind randomized placebo controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis2003; 15: 289–300.
49.
GusevYIBanachMSimonowA. Efficacy and safety of Botulinum toxin Type A Toxin in Adductor spasticity due to Multiple Scelrosis. J Musculoskelet Pain2008; 16(3): 175–188.
50.
DunneJWGraciesJ-MHayesMZemanBSingerBJ. A prospective, multicenter, randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA to treat plantarflexor/invertor overactivity after stroke. Clin Rehabil2012; 26(9): 787–797.
51.
RichardsonDSheeanGWerringD. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry2000; 69: 499–506.
52.
BrashearAGordonMFElovicE. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med2002; 347(6): 395–400.
53.
JahangirAWTanHJNorlinahMI. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. Med J Malaysia2007; 62(4): 319–322.
54.
SmithSJEllisEWhiteS. A double-blind, placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil2000; 14: 5–13.
55.
KajiROsakoYSuyamaK. Botulinum toxin type A in post-stroke upper limb spasticity. Curr Med Res Opinion2010; 26(8): 1983–1992.
56.
SimpsonDMGraciesJMYablonSABarbanoRBrashearA. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo controlled study. J Neurol Neurosurg Psychiatry2009; 80: 380–385.
57.
MeythalerJMVogtleLBrunnerRC. A preliminary assessment of the benefits of the addition of botulinum toxin A to a conventional therapy program on the function of people with longstanding stroke. Arch Phys Med Rehabil2009; 90: 1453–1461.
58.
WolfSLMiltonBReissAEasleyKAShenviNVClarkPC. Further assessment to determine the additive effect of Botulinum Toxin type A on an upper extremity exercise program to enhance function among individuals with chronic stroke but extensor capability. Arch Phys Med Rehabil2012; 93(4): 578–587.
59.
HesseSMachHFrohlichSBehrendSWernerCMelzerI. An early Botulinum Toxin A treatment in subacute stroke patients may prevent a disabling finger flexor stiffness six months later: A randomised controlled trial. Clin Rehabil2012; 26(3): 237–245.
60.
BhaktaBBO’ConnorRJCozensJA. Associated Reactions after stroke: a randomised controlled trial of the effect of botulinum toxin type A. J Rehabil Med2008; 40: 36–41.
61.
CousinsEWardARoffeCRimingtonL. Does low dose botulinum toxin help the recovery of arm function when given early after stroke? A phase II randomised controlled pilot study to estimate effect size. Clin Rehabil2010; 24: 501–513.
62.
MaanumGJahnsenRStanghelleJK. Effects of botulinum toxin A in ambulant adults with spastic cerebral palsy: a randomised double blind placebo controlled trial. J Rehabil Med2011; 43: 338–347.
63.
KajiROsakoYSuyamaK. Botulinum toxin type A in post stroke lower limb spasticity: a multicenter, double blind, placebo controlled trial. J Neurol2010; 257: 1330–1337.
64.
BurbaudPWiartLDubosJL. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry1996; 61(3): 265–269.
65.
VerplanckeDSnapeSSalisburyCF. A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clin Rehabil2005; 19: 117–125.
66.
SnowBJTsuiJKCBhattMHVarelasMHashimotoSACalneDB. Treatment of spasticity with botulinum toxin: a double blind study. Annals Neurol1990; 28(4): 512–515.
67.
SheeanGLanninNATurner-StokesLRawickiBSnowBJ. Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement. Eur J Neurol2010; 17(S2): 74–93.
68.
WisselJMullerJDressnandtJ. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage2000; 20(1): 44–49.
69.
PatrickEAdaL. The Tardieu scale differentiates contracture from spasticity whereas the Ashworth scale is confounded by it. Clin Rehabil2006; 20: 173–182.
70.
MalhotraSCousinsEWardA. An investigation into the agreement between clinical, biomechanical and neurophysiological measures of spasticity. Clin Rehabil2008; 22: 1105–1115.
71.
LiberatiAAltmanDGTetzlaffJ. The PRISMA Statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med2009; 151: W65–W94.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
